Accelerated Holding Corp. OBP IV
New York, NY

Accelerated Holding creates and efficiently develops new enterprises within the medical technology arena, focusing on the cardiovascular market, by leveraging its infrastructure and the know-how of involved clinicians and researchers.

 
Affinium Pharmaceuticals, Ltd. OBP V
Toronto, Ontario, Canada
www.afnm.com

Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Their lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections.

 
Applied Spine Technologies, Inc. OBP IV
Rocky Hill, CT
www.appliedspine.com

Applied Spine Technologies is a spine company focused on developing implantable dynamic stabilization systems for the treatment of chronic back pain.

 
Astex Therapeutics Ltd. OBP II, III
Cambridge, UK
www.astex-therapeutics.com

Astex is a drug discovery company applying novel protein structure-based technologies for the discovery of small molecule therapeutics.

 
AVEO Pharmaceuticals, Inc. OBP IV
Cambridge, MA
www.aveopharma.com

AVEO is a cancer therapeutics discovery company using in vivo tumor models and focusing on tumor maintenance genes.

 
BrainCells Inc. OBP IV
La Jolla, CA
www.braincellsinc.com

BrainCells Inc. is a neurogenesis-based drug discovery and development company targeting novel therapies for disorders of mood and anxiety.

 
Cambrios Technologies Corp. OBP IV
Sunnyvale, CA
www.cambrios.com

Cambrios Technologies Corp. applies peptide affinity and biological patterning technologies to commercially important materials in semiconductor and other industries. Cambrios’ technologies enable rapid and low cost formation of patterned thin films of essentially any material, and are of particular use in large area electronic applications such as flat panel displays.

 
CardioFocus, Inc. OBP III
Marlborough, MA
www.cardiofocus.com

CardioFocus develops laser-based technology for the treatment of the underlying causes of atrial fibrillation.

 
Ceres, Inc. OBP II
Thousand Oaks, CA
www.ceres.net

Ceres is a plant genomics company identifying key genes determining seed size, quantity, and yield amounts, as well as pesticide and herbicide resistance.

 
CGI Pharmaceuticals Inc. OBP V
Branford, CT
www.cgipharma.com

CGI Pharmaceuticals is dedicated to the discovery and development of small molecule kinase inhibitors for autoimmune/allergic/inflammatory disease (AAID) indications and oncology/angiogenesis.

 
CircuLite, Inc. OBP IV
Saddle Brook, NJ and Aachen, Germany
www.circulite.net

CircuLite develops superficially implanted ventricular assist devices to treat congestive heart failure that align with the operating skills of the interventional cardiologist.

 
Claros Diagnostics, Inc. OBP V
Woburn, MA
www.clarosdx.com

Claros Diagnostics is developing point-of-care medical diagnostic instruments which allow laboratory-quality testing to be performed directly by physicians and healthcare professionals. The company’s initial product is an immunoassay system providing urologists with quantitative blood-based results in minutes.

 
Coherex Medical, Inc. OBP V
www.coherex.com
Salt Lake City, UT

Coherex Medical is developing safer technologies such as a minimally invasive implant to close a heart defect called a patent foramen ovale, or PFO, and to induce tissue growth. PFO has been linked to at least two medical conditions that may benefit greatly from closure: cryptogenic stroke and migraine.

 
Concentric Medical, Inc. OBP IV
Mountain View, CA
www.concentric-medical.com

Concentric Medical is building a franchise in neurovascular intervention by developing new device-based treatments for ischemic and hemorrhagic stroke. Concentric’s leading product, the proprietary MERCI™ System has the potential of revolutionizing ischemic stroke intervention by providing a simple and innovative mechanical method of removing thrombus to restore blood flow.

 
Decision Biomarkers, Inc. OBP IV
Waltham, MA
www.decisionbiomarkers.com

Decision Biomarkers is developing a multiplexed immunoassay technology to simultaneously analyze 20-40 different protein biomarkers.

 
Dicerna Pharmaceuticals, Inc. OBP V
Cambridge, MA
www.dicerna.com

Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.

 
Elixir Pharmaceuticals, Inc. OBP III
Cambridge, MA
www.elixirpharm.com

Elixir is a drug discovery company developing therapeutics to treat age-related diseases, with a focus on metabolic diseases such as diabetes and obesity.

 
Enanta Pharmaceuticals, Inc. OBP III
Watertown, MA
www.enanta.com

Enanta Pharmaceuticals is using its cutting-edge chemistry technology and drug discovery capabilities to create best in class small molecule drugs. The company is initially focused on building a pipeline of first generation bridged bicyclic macrolide and ketolide antibiotics to combat bacterial resistance in the treatment of respiratory tract infections (RTI) and hospital borne diseases.

 
Ensemble Discovery, Inc. OBP IV
Cambridge, MA
www.ensemblediscovery.com

Utilizes its novel DNA Programmed Chemistry to direct synthetic organic chemical reactions in order to overcome the limitations - such as speed, expense and structural diversity - of methods currently used to generate novel small molecules.

 
GloriOil Limited OBP V
Houston, TX
www.glorioil.com

GloriOil delivers state of the art bio-technology solutions to improve production and increase recovery from mature oil wells.

 
HydroCision, Inc. OBP III
Billerica, MA
www.hydrocision.com

HydroCision develops minimally invasive surgical products using a fluid jet technology for cutting and ablating tissue with applications in orthopedics, urology, and gynecology.

 
ImpactRx, Inc. OBP III
Mt. Laurel, NJ
www.impactrx.com

ImpactRx is a promotion research company providing detailed analysis of the effects of pharmaceutical company promotion efforts. ImpactRx builds exclusive networks of high-prescribing physicians who provide real-time diagnosis, drug and promotion information.

 
IntraPace, Inc. OBP IV
Menlo Park, Ca
www.intrapace.com

IntraPace is developing an endoscopically delivered gastric pacemaker for obesity treatment.

 
Laboratory Partners, Inc. OBP IV
Palo Alto, CA

Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.

 
Luca Technologies OBP V
Golden, CO
www.lucatechnologies.com

Luca Technologies is developing a novel, long-term, biotechnology-driven solution to rising U.S. dependence on foreign energy sources.

 
Mitralign, Inc. OBP IV
Tewksbury, MA
www.mitralign.com

Develops a novel percutaneous transcatheter medical device for the treatment of mitral valve regurgitation, a disorder than can either cause or be exacerbated by congestive heart failure.

 
Molecular Biometrics, Inc. OBP V
Norwood, MA
www.molecularbiometrics.com

Molecular Biometrics, Inc. develops highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics. The Company’s first target market is reproductive health and infertility where it intends to introduce its non-invasive procedures for gamete and embryo viability assessment for in-vitro fertilization (IVF).

 
nFocus Neuromedical, Inc. OBP V
Menlo Park, CA
www.nfocusneuro.com

nFocus develops innovative next generation neurovascular devices for the treatment of wide neck aneurysms and large arterio-venous malformations (AVMs).

 
Pathway Medical Technologies, Inc. OBP V
Kirkland, WA
www.pathwaymedical.com

Pathway is developing catheter technology to remove and aspirate thrombus in coronary arteries, bypass grafts and other arteries.

 
Radius OBP IV
Cambridge, MA
www.radiuspharm.com

Radius is a privately held company that is a leader in the discovery and development of a new generation of drug therapies for osteoporosis and women’s health.

 
Rib-X Pharmaceuticals, Inc. OBP IV
New Haven, CT
www.rib-x.com

Rib-X uses structure-based drug design to discover new classes of antibiotics based on the high-resolution crystal structure of the 50s ribosomal subunit.

 
SmartPill Corporation OBP V
Buffalo, NY
www.smartpillcorp.com

The SmartPill Corporation is a developer and manufacturer of ingestible, capsule-based medical devices that aid in the diagnosis, definition and therapeutic intervention of gastrointestinal disorders and diseases. Their flagship product, the SmartPill pH.p., is an ingestible capsule that measures acidity, pressure and temperature within the entire GI tract to diagnose GI motility disorders. This ‘pill’ is currently FDA approved to diagnose certain GI conditions.


 
Solstice Neurosciences, Inc. OBP IV
Malvern, PA and South San Francisco, CA
www.solsticeneuro.com

Solstice Neurosciences is a specialty biopharmaceutical company focused on the neurology market. Solstice's first product, Myobloc (Botulinum Toxin Type B), is currently approved in the USA and Europe for use in cervical dystonia.

 
superDimension, Ltd. OBP IV
Herzliya, Israel and Plymouth, MN
www.superdimension.com

superDimension has a minimally invasive technology platform for interventional pulmonology, providing clinicians with 3-D visualization. This enables physicians to direct a variety of instruments through the lungs.

 
Tragara Pharmaceuticals, Inc. OBP V
San Diego, CA
www.tragarapharma.com

Tragara Pharmaceuticals, Inc. is a clinical-stage oncology specialty pharmaceuticals company focusing on the development of therapeutics in cancer and inflammation related disorders.

 
VaxInnate Corporation OBP IV
Cranbury, NJ and New Haven, CT
www.vaxinnate.com

VaxInnate is developing prophylactic and therapeutic vaccines; technology based on research and discoveries of leading scientists from Yale University.

 
Xencor, Inc. OBP V
Monrovia, CA
www.xencor.com

Xencor is a later-stage company that has successfully developed a protein engineering technology and has used that technology to develop a clinical pipeline. Xencor has partnered with leading biotech companies, including Genentech and Eli Lilly and is designing next-generation protein drug candidates with improved selectivity, efficacy and safety.

 
ZettaCore, Inc. OBP IV
Englewood, CO and Los Altos, CA
www.zettacore.com

ZettaCore applies life science technology to the semiconductor manufacturing process by utilizing porphyrin bio-molecules to create molecular memory for electronic storage devices.